What Criteria Qualify Nasal Polyps for Biologic Therapy?

Criteria for starting biologic therapy are based on demonstrating that your nasal polyps are “inadequately controlled” despite proper medical treatment. The specific hurdles you must cross depend on a combination of medical guidelines, regulatory labels, and your individual insurance plan’s step-therapy rules. Generally, it involves documenting the presence of bilateral polyps on an endoscopy, proving that you have consistently tried standard treatments like steroid sprays, and showing that you have severe symptoms, specific markers of inflammation, or a history of needing oral steroids or sinus surgery.

The Difference Between Guidelines, Approvals, and Insurance

It’s important to understand that there is no single universal law that determines who gets biologics. Instead, three different sets of rules overlap:

• Medical Guidelines: The most widely cited framework is the EPOS 2020 (European Position Paper on Rhinosinusitis and Nasal Polyps). It provides a clinical checklist for doctors to identify the most severe cases ^[1].
• Regulatory Approval: Government agencies (like the FDA or EMA) approve these drugs for severe chronic rhinosinusitis with nasal polyps that is inadequately controlled ^[2]. Their prescribing labels generally focus on the failure of standard treatments rather than demanding a mandatory prior surgery or specific blood test cutoff.
• Insurance Plan Policies: Your specific insurance company or national health system has its own prior authorization rules. Insurers often use “step therapy,” requiring documentation that cheaper, standard treatments did not work before they will pay for a biologic ^[3].

Baseline Requirements: Proving “Inadequately Controlled” Disease

Dealing with recurrent polyps after years of sprays, pills, or surgeries is deeply frustrating. Before biologics are considered, your medical records typically need to establish a baseline of severe, persistent disease:

• Objective Evidence of Bilateral Polyps: Your doctor must document polyps in both sides of your nose. This is usually done with a nasal endoscopy (a small camera looking directly into the nose) ^[4]. A CT scan can show sinus blockage and support the diagnosis, but endoscopy is generally preferred to directly visualize the polyps ^[5].
• Persistent Symptoms Despite Treatment: You must have tried standard medical therapies. This means consistent, long-term use of intranasal corticosteroid sprays or rinses ^[6]. Biologics are designed to be an “add-on” therapy; they target specific inflammatory pathways systemically, but you will generally continue your local nasal steroid sprays even after starting the injections ^{[7] [8]}.
• Prior Treatments (Steroid Pills or Surgery): While regulatory labels don’t always mandate it, many insurance plans and the EPOS guidelines look for a history of needing systemic (oral) steroids or having prior surgery. They often want to see that you have required short courses of oral steroid pills in the past year, or have previously undergone Functional Endoscopic Sinus Surgery (FESS) only to have the polyps return ^[9]. If you have a medical condition that makes surgery or oral steroids unsafe for you, your specialist will need to document that ^{[9] [1]}.

The EPOS 2020 “3 out of 5” Framework

To help specialists identify patients who are the best candidates, the EPOS 2020 guidelines suggest that patients (often those who have already had FESS or who cannot undergo surgery) should meet at least three of the following five criteria ^{[9] [1]}:

1. Evidence of Type 2 Inflammation: The doctor looks for markers of the specific inflammatory pathway these drugs target. EPOS uses thresholds like blood eosinophils ≥250 cells/µL, polyp tissue eosinophils ≥10 per high-power field, or total IgE ≥100 IU/mL ^[10]. (Note: A normal blood test does not automatically disqualify you under all insurance plans, and tissue tests are only available if you’ve had a biopsy or surgery).
2. Need for Systemic Steroids: You have required multiple courses of oral steroids in the past year, or you have a medical contraindication to taking them ^[9].
3. Severe Loss of Smell: You have significant impairment or total loss of smell (anosmia), which may be confirmed with formal smell testing ^[1].
4. Significantly Impaired Quality of Life: Your symptoms severely impact your daily life, often measured by a score of ≥40 on a standard symptom questionnaire called the SNOT-22 ^[9].
5. Comorbid Asthma: You also have asthma that requires regular treatment with an inhaled corticosteroid ^[11].

Navigating Insurance Authorization and Next Steps

If you and your doctor decide a biologic is the right next step, your doctor’s office will compile an eligibility worksheet of your records. This includes your endoscopy findings, SNOT-22 scores, smell test results, blood work, and history of standard treatments, which they will submit to your insurance ^{[4] [3]}.

Approval rules vary widely. For instance, while EPOS emphasizes prior surgery, some clinical trials and US insurance pathways allow patients to qualify if they have needed frequent oral steroids, even without prior surgery ^{[12] [13]}.

If approved, you will begin the injections (administered at home or in a clinic) while continuing your daily nasal steroid sprays ^[2]. Your doctor will typically assess your response after 4 to 6 months ^[14]. To renew your prescription, insurers commonly require documentation that the medication is actually working—such as improved smell, a reduced need for oral steroids, or visibly smaller polyps on endoscopy ^{[15] [3]}.